IBIan H. Batty

Ian H. Batty

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ian H. Batty has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • C. Peter Downes

    ‖Department of Pharmacology, University of Toronto, Toronto, Ontario M5G 1L5, Canada

    4 shared publications
  • Miles J. Dixon

    Division of Cell Signalling and Immunology, College of Life Sciences, University of Dundee, Dow St., Dundee DD1 5EH, Scotland, United Kingdom

    3 shared publications
  • Alexander Gray

    Leverhulme Research Centre for Forensic Science, Fleming Gym Building, University of Dundee, Small's Wynd, Dundee, United Kingdom

    2 shared publications
  • Mark Agacan

    ‖Department of Pharmacology, University of Toronto, Toronto, Ontario M5G 1L5, Canada

    2 shared publications
  • Nicholas R. Leslie

    School of Engineering and Physical Sciences, Heriot-Watt University, UK

    2 shared publications
  • Alex Gray

    The Division of Molecular Physiology, School of Life Sciences, The James Black Centre, University of Dundee, Dow St, Dundee DD1 5EH, Scotland, U.K.

    1 shared publication

Latest Publications

  • Open Access

    IQGAP Proteins Reveal an Atypical Phosphoinositide (aPI) Binding Domain with a Pseudo C2 Domain Fold

    by Miles J. Dixon, Alexander Gray, Martijn Schenning, Mark Agacan, Wolfram Tempel, Yufeng Tong, Lyudmila Nedyalkova, Hee-Won Park, Nicholas R. Leslie, Daan M. F. van Aalten, et al.


  • Open Access

    A Screen for Novel Phosphoinositide 3-kinase Effector Proteins

    by Miles J. Dixon, Alexander Gray, François-Michel Boisvert, Mark Agacan, Nicholas A. Morrice, Robert Gourlay, Nicholas R. Leslie, C. Peter Downes, Ian H. Batty


  • The control of phosphatidylinositol 3,4-bisphosphate concentrations by activation of the Src homology 2 domain containing inositol polyphosphate 5-phosphatase 2, SHIP2

    by Ian H. Batty, Jeroen van der Kaay, Alex Gray, Joan F. Telfer, Miles J. Dixon, C. Peter Downes

    Activation of class Ia PI3K (phosphoinositide 3-kinase) produces PtdInsP3, a vital intracellular mediator whose degradation generates additional lipid signals. In the present study vanadate analogues that inhibit PTPs (protein tyrosine phosphatases) were used to probe the mechanisms which regulate the concentrations of these molecules allowing their independent or integrated function. In 1321N1 cells, which lack PtdInsP3 3-phosphatase activity, sodium vanadate or a cell permeable derivative, bpV(phen) [potassium bisperoxo(1,10-phenanthroline)oxovanadate (V)], increased the recruitment into anti-phosphotyrosine immunoprecipitates of PI3K activity and of the p85 and p110α subunits of class Ia PI3K and enhanced the recruitment of PI3K activity stimulated by PDGF (platelet-derived growth factor). However, neither inhibitor much increased cellular PtdInsP3 concentrations, but both diminished dramatically the accumulation of PtdInsP3 stimulated by PDGF or insulin and markedly increased the control and stimulated concentrations of PtdIns(3,4)P2. These actions were accounted for by the ability of PTP inhibitors to stimulate the activity of endogenous PtdInsP3 5-phosphatase(s), particularly SHIP2 (Src homology 2 domain containing inositol polyphosphate 5-phosphatase 2) and to inhibit types I and II PtdIns(3,4)P2 4-phosphatases. Thus bpV(phen) promoted the translocation of SHIP2 from the cytosol to a Triton X-100-insoluble fraction and induced a marked (5–10-fold) increase in SHIP2 specific activity mediated by enhanced tyrosine phosphorylation. The net effect of these inhibitors was, therefore, to switch the signal output of class I PI3K from PtdInsP3 to PtdIns(3,4)P2. A key component controlling this shift in the balance of lipid signals is the activation of SHIP2 by increased tyrosine phosphorylation, an effect observed in HeLa cells in response to both PTP inhibitors and epidermal growth factor.


  • Muscarinic-receptor-mediated inhibition of insulin-like growth factor-1 receptor-stimulated phosphoinositide 3-kinase signalling in 1321N1 astrocytoma cells

    by Ian H. Batty, Ian N. Fleming, C. Peter Downes

    In 1321N1 astrocytoma cells, stimulation of the IGF-1 (insulin-like growth factor-1) receptor increased the association of PI3K [phosphoinositide (PI) 3-kinase] activity with IRS-1 (insulin re-ceptor substrate 1), and increased the cellular concentration of PtdIns(3,4,5)P3. Carbachol, acting on M3 muscarinic receptors, inhibited insulin-, but not PDGF (platelet-derived growth factor)-, stimulated responses by ≈50%. The inhibition of IRS-1-associated PI3K activity by carbachol (i) was rapid (<1 min), persistent (≥60 min) and potent (half-maximal concentration ≈1 µM); (ii) was reproduced by stimuli for several phospholipase-C-coupled receptors; (iii) was prevented by the inhibition of protein kinase C, but not by chelation of intracellular Ca2+; and (iv) was not blocked or reproduced by inhibitors or stimuli respectively of mitogen-activated protein kinase, PI3K, protein kinase B or the mammalian target of rapamycin. However, the effects of carbachol were prevented by sodium vanadate, a protein tyrosine phosphatase inhibitor, and were accompanied by reduced insulin-stimulated IRS-1 tyrosine phosphorylation and recruitment of the 85 kDa regulatory subunit of PI3K to IRS-1, but not by reduced IGF-1 receptor kinase activity. The inhibitory effect of carbachol was reproduced by okadaic acid, a protein serine/threonine phosphatase inhibitor, but not by PDGF, yet all three agents stimulated the serine phosphorylation of IRS-1 at residues Ser312, Ser616 and Ser636/639, albeit to different extents. Thus muscarinic receptors may inhibit insulin signalling by promoting IRS-1 tyrosine dephosphorylation and/or by uncoupling IRS-1 from the stimulated IGF-1 receptor by stimulating IRS-1 serine phosphorylation. However, the proportion of IRS-1 molecules phosphorylated at a particular site or the phosphorylation of additional IRS-1 serine residues other than those noted above must be important.